AIM ImmunoTech Inc. (AIM)
USD 0.09
(-19.37%)
USD 0.09
(-19.37%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -31.91 Million USD | -60.2% |
| 2022 | -19.92 Million USD | -5.76% |
| 2021 | -18.83 Million USD | -24.33% |
| 2020 | -15.15 Million USD | -21.77% |
| 2019 | -12.44 Million USD | -8.24% |
| 2018 | -11.49 Million USD | -0.7% |
| 2017 | -11.41 Million USD | 17.3% |
| 2016 | -13.8 Million USD | 17.09% |
| 2015 | -16.65 Million USD | 12.82% |
| 2014 | -19.09 Million USD | -11.25% |
| 2013 | -17.16 Million USD | 15.6% |
| 2012 | -20.34 Million USD | -42.29% |
| 2011 | -14.29 Million USD | 12.77% |
| 2010 | -16.38 Million USD | -23.54% |
| 2009 | -13.26 Million USD | -3.54% |
| 2008 | -12.81 Million USD | 33.58% |
| 2007 | -19.28 Million USD | -3.18% |
| 2006 | -18.69 Million USD | -93.94% |
| 2005 | -9.63 Million USD | 11.48% |
| 2004 | -10.88 Million USD | -50.15% |
| 2003 | -7.25 Million USD | -9.55% |
| 2002 | -6.62 Million USD | 24.79% |
| 2001 | -8.8 Million USD | 2.67% |
| 2000 | -9.04 Million USD | 5.8% |
| 1999 | -9.6 Million USD | -33.33% |
| 1998 | -7.2 Million USD | -12.5% |
| 1997 | -6.4 Million USD | -33.33% |
| 1996 | -4.8 Million USD | -380.0% |
| 1995 | -1 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -5.73 Million USD | 59.01% |
| 2024 Q2 | -3.69 Million USD | 35.58% |
| 2023 Q4 | -13.99 Million USD | -78.99% |
| 2023 Q2 | -5.46 Million USD | -27.15% |
| 2023 Q3 | -7.81 Million USD | -43.12% |
| 2023 Q1 | -4.29 Million USD | 22.7% |
| 2023 FY | -31.9 Million USD | -60.13% |
| 2022 Q1 | -3.15 Million USD | 57.66% |
| 2022 FY | -19.92 Million USD | -5.76% |
| 2022 Q4 | -5.55 Million USD | 14.8% |
| 2022 Q3 | -6.52 Million USD | -38.89% |
| 2022 Q2 | -4.69 Million USD | -48.95% |
| 2021 Q3 | -3.92 Million USD | -5.68% |
| 2021 FY | -18.83 Million USD | -24.33% |
| 2021 Q4 | -7.44 Million USD | -89.49% |
| 2021 Q1 | -3.74 Million USD | 27.28% |
| 2021 Q2 | -3.71 Million USD | 0.72% |
| 2020 Q2 | -3.34 Million USD | -0.45% |
| 2020 Q4 | -5.15 Million USD | -53.5% |
| 2020 Q3 | -3.35 Million USD | -0.45% |
| 2020 FY | -15.15 Million USD | -21.77% |
| 2020 Q1 | -3.32 Million USD | -7.67% |
| 2019 Q2 | -3.22 Million USD | -10.18% |
| 2019 Q3 | -3.2 Million USD | 0.59% |
| 2019 FY | -12.44 Million USD | -8.24% |
| 2019 Q4 | -3.08 Million USD | 3.65% |
| 2019 Q1 | -2.92 Million USD | -9.96% |
| 2018 Q3 | -3.03 Million USD | 5.86% |
| 2018 Q1 | -2.57 Million USD | 7.98% |
| 2018 Q4 | -2.66 Million USD | 12.41% |
| 2018 FY | -11.49 Million USD | -0.7% |
| 2018 Q2 | -3.22 Million USD | -25.56% |
| 2017 Q2 | -2.73 Million USD | 15.77% |
| 2017 Q4 | -2.79 Million USD | -5.32% |
| 2017 Q1 | -3.24 Million USD | 20.66% |
| 2017 FY | -11.41 Million USD | 17.3% |
| 2017 Q3 | -2.65 Million USD | 2.86% |
| 2016 FY | -13.8 Million USD | 17.09% |
| 2016 Q1 | -3.67 Million USD | -29.41% |
| 2016 Q2 | -2.81 Million USD | 23.51% |
| 2016 Q3 | -3.22 Million USD | -14.64% |
| 2016 Q4 | -4.08 Million USD | -26.63% |
| 2015 Q3 | -3.98 Million USD | 18.73% |
| 2015 Q1 | -4.92 Million USD | -7.65% |
| 2015 Q4 | -2.84 Million USD | 28.62% |
| 2015 Q2 | -4.9 Million USD | 0.45% |
| 2015 FY | -16.65 Million USD | 12.82% |
| 2014 Q1 | -5.11 Million USD | -49.82% |
| 2014 Q4 | -4.57 Million USD | -5.64% |
| 2014 FY | -19.09 Million USD | -11.25% |
| 2014 Q2 | -5.08 Million USD | 0.53% |
| 2014 Q3 | -4.32 Million USD | 14.87% |
| 2013 Q1 | -4.56 Million USD | 42.94% |
| 2013 Q4 | -3.41 Million USD | 23.48% |
| 2013 FY | -17.16 Million USD | 15.6% |
| 2013 Q3 | -4.45 Million USD | 5.81% |
| 2013 Q2 | -4.73 Million USD | -3.77% |
| 2012 Q3 | -4.96 Million USD | -36.66% |
| 2012 Q2 | -3.63 Million USD | 3.04% |
| 2012 Q1 | -3.74 Million USD | 3.92% |
| 2012 Q4 | -7.99 Million USD | -61.03% |
| 2012 FY | -20.34 Million USD | -42.29% |
| 2011 Q3 | -3.55 Million USD | -9.51% |
| 2011 Q2 | -3.24 Million USD | 9.53% |
| 2011 Q1 | -3.59 Million USD | 26.03% |
| 2011 FY | -14.29 Million USD | 12.77% |
| 2011 Q4 | -3.9 Million USD | -9.64% |
| 2010 Q2 | -3.76 Million USD | 7.46% |
| 2010 Q3 | -3.69 Million USD | 2.04% |
| 2010 Q4 | -4.85 Million USD | -31.45% |
| 2010 Q1 | -4.07 Million USD | -2.49% |
| 2010 FY | -16.38 Million USD | -23.54% |
| 2009 Q4 | -3.97 Million USD | -61.68% |
| 2009 FY | -13.26 Million USD | -3.54% |
| 2009 Q1 | -2.85 Million USD | 4.42% |
| 2009 Q2 | -3.97 Million USD | -39.47% |
| 2009 Q3 | -2.45 Million USD | 38.23% |
| 2008 FY | -12.81 Million USD | 33.58% |
| 2008 Q4 | -2.98 Million USD | 13.5% |
| 2008 Q3 | -3.45 Million USD | -10.26% |
| 2008 Q1 | -3.24 Million USD | 19.12% |
| 2008 Q2 | -3.13 Million USD | 3.54% |
| 2007 Q2 | -4.15 Million USD | 15.83% |
| 2007 Q3 | -6.17 Million USD | -48.61% |
| 2007 Q1 | -4.94 Million USD | -11.76% |
| 2007 Q4 | -4.01 Million USD | 35.07% |
| 2007 FY | -19.28 Million USD | -3.18% |
| 2006 Q3 | -3.86 Million USD | 19.92% |
| 2006 FY | -18.69 Million USD | -93.94% |
| 2006 Q2 | -4.82 Million USD | 13.62% |
| 2006 Q4 | -4.42 Million USD | -14.39% |
| 2006 Q1 | -5.58 Million USD | -82.31% |
| 2005 Q1 | -2.09 Million USD | -11.17% |
| 2005 Q4 | -3.06 Million USD | -44.87% |
| 2005 FY | -9.63 Million USD | 11.48% |
| 2005 Q2 | -2.37 Million USD | -13.4% |
| 2005 Q3 | -2.11 Million USD | 10.76% |
| 2004 FY | -10.88 Million USD | -50.15% |
| 2004 Q1 | -4.1 Million USD | -81.62% |
| 2004 Q2 | -2.19 Million USD | 46.48% |
| 2004 Q3 | -2.71 Million USD | -23.64% |
| 2004 Q4 | -1.88 Million USD | 30.73% |
| 2003 FY | -7.25 Million USD | -9.55% |
| 2003 Q4 | -2.25 Million USD | -27.86% |
| 2003 Q3 | -1.76 Million USD | -7.95% |
| 2003 Q1 | -1.59 Million USD | -25.65% |
| 2003 Q2 | -1.63 Million USD | -2.76% |
| 2002 Q1 | -1.5 Million USD | 9.38% |
| 2002 Q4 | -1.26 Million USD | 32.68% |
| 2002 Q3 | -1.88 Million USD | 4.13% |
| 2002 Q2 | -1.96 Million USD | -30.17% |
| 2002 FY | -6.62 Million USD | 24.79% |
| 2001 Q2 | -2.4 Million USD | 5.73% |
| 2001 Q3 | -2.18 Million USD | 9.03% |
| 2001 Q4 | -1.66 Million USD | 23.88% |
| 2001 FY | -8.8 Million USD | 2.67% |
| 2001 Q1 | -2.54 Million USD | -0.45% |
| 2000 Q3 | -2.18 Million USD | 0.29% |
| 2000 FY | -9.04 Million USD | 5.8% |
| 2000 Q2 | -2.19 Million USD | -3.29% |
| 2000 Q1 | -2.12 Million USD | -6.2% |
| 2000 Q4 | -2.53 Million USD | -16.0% |
| 1999 FY | -9.6 Million USD | -33.33% |
| 1999 Q4 | -2 Million USD | 0.0% |
| 1999 Q3 | -2 Million USD | 25.93% |
| 1999 Q2 | -2.7 Million USD | 10.0% |
| 1999 Q1 | -3 Million USD | -57.89% |
| 1998 Q1 | -1.6 Million USD | -6.67% |
| 1998 Q2 | -1.7 Million USD | -6.25% |
| 1998 Q3 | -1.8 Million USD | -5.88% |
| 1998 FY | -7.2 Million USD | -12.5% |
| 1998 Q4 | -1.9 Million USD | -5.56% |
| 1997 Q2 | -1.1 Million USD | 54.17% |
| 1997 Q3 | -1.5 Million USD | -36.36% |
| 1997 FY | -6.4 Million USD | -33.33% |
| 1997 Q4 | -1.5 Million USD | 0.0% |
| 1997 Q1 | -2.4 Million USD | -71.43% |
| 1996 Q1 | -700 Thousand USD | 77.42% |
| 1996 Q4 | -1.4 Million USD | 6.67% |
| 1996 FY | -4.8 Million USD | -380.0% |
| 1996 Q3 | -1.5 Million USD | -50.0% |
| 1996 Q2 | -1 Million USD | -42.86% |
| 1995 Q4 | -3.1 Million USD | -542.86% |
| 1995 Q3 | 700 Thousand USD | 0.0% |
| 1995 Q1 | 700 Thousand USD | 0.0% |
| 1995 Q2 | 700 Thousand USD | 0.0% |
| 1995 FY | -1 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Ampio Pharmaceuticals, Inc. | -9.51 Million USD | -235.323% |
| Armata Pharmaceuticals, Inc. | -40.89 Million USD | 21.947% |
| Actinium Pharmaceuticals, Inc. | -51.92 Million USD | 38.529% |
| Azitra, Inc. | -7.61 Million USD | -319.043% |
| Can-Fite BioPharma Ltd. | -8.19 Million USD | -289.457% |
| Chromocell Therapeutics Corporation | -6.86 Million USD | -365.093% |
| Calidi Biotherapeutics, Inc. | -28.99 Million USD | -10.086% |
| CEL-SCI Corporation | -31.47 Million USD | -1.398% |
| iBio, Inc. | -16.63 Million USD | -91.872% |
| Lineage Cell Therapeutics, Inc. | -24.73 Million USD | -29.042% |
| MAIA Biotechnology, Inc. | -20.18 Million USD | -58.138% |
| Matinas BioPharma Holdings, Inc. | -23.76 Million USD | -34.293% |
| Navidea Biopharmaceuticals, Inc. | -14.05 Million USD | -127.146% |
| NovaBay Pharmaceuticals, Inc. | -5 Million USD | -537.937% |
| NanoViricides, Inc. | -8.51 Million USD | -274.772% |
| Oragenics, Inc. | -20.9 Million USD | -52.672% |
| BiomX Inc. | -27.68 Million USD | -15.283% |
| BiomX Inc. | -27.68 Million USD | -15.283% |
| Protalix BioTherapeutics, Inc. | 10.46 Million USD | 405.124% |
| Palatin Technologies, Inc. | -22.49 Million USD | -41.873% |
| Scorpius Holdings, Inc. | -42.03 Million USD | 24.068% |
| Theriva Biologics, Inc. | -21.43 Million USD | -48.924% |